Carbon-ion radiotherapy for locally recurrent rectal cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1404 Rectum. (March 2019)

• Record Type: Journal Article
• Authors: Shinoto, Makoto; Yamada, Shigeru; Okamoto, Masahiko; Shioyama, Yoshiyuki; Ohno, Tatsuya; Nakano, Takashi; Nemoto, Kenji; Isozaki, Yuka; Kawashiro, Shohei; Tsuji, Hiroshi; Kamada, Tadashi
• Is Part Of: Radiotherapy and oncology. Volume 132(2019)
• Page Start: 236
• Page End: 240
• Publication Date: 2019-03
• Subjects: Carbon-ion radiotherapy -- Locally recurrent rectal cancer -- Multi-institution -- Clinical trial; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2018.10.007
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: We analyzed 224 LRRC patients treated with C-ion RT at three institutions. The median follow-up period from the initiation of C-ion RT was 62 months. The OS rates were 73% at 3 years and 51% at 5 years. Grade 3 acute ( n = 3) and grade 3 late ( n = 12) toxicity was observed. C-ion RT for LRRC showed relatively favorable outcomes and limited toxicity. Abstract: Purpose: We investigated the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for locally recurrent rectal cancer (LRRC). Patients and methods: Data from patients with LRRC treated with C-ion RT from November 2003 to December 2014 at three institutions were retrospectively analyzed. The endpoints of this clinical trial were overall survival (OS), local control (LC), and acute/late toxicity. Results: A total of 224 patients' data were collected. The prescribed dose was 70.4 Gy (relative biological effectiveness [RBE]-weighted absorbed dose) or 73.6 Gy (RBE) in 16 fractions. The median follow-up period from the initiation of C-ion RT was 62 months (range 6–169 months). The OS rates were 73% (95% confidence interval [CI], 67%–79%) at 3 years and 51% (95%CI 44%–58%) at 5 years. The LC rates were 93% (95%CI 88%–96%) at 3 years, and 88% (95%CI 82%–93%) at 5 years. Grade 3 acute toxicity was observed in three patients: gastrointestinal toxicity ( n = 1) and pelvic infection ( n = 2). Grade 3 late toxicity was observed in 12 patients: skin reaction ( n = 2), gastrointestinal toxicity ( n = 2), neuropathy ( n = 1), and pelvic infection ( n = 7). There was no grade 4 or 5 acute or late toxicity. Conclusions: This first multi-institutional analysis of C-ion RT for LRRC indicated relatively favorable outcomes with limited toxicities.